Fig. 3

Effects of vidarabine on PG-LPS-induced cardiac myocyte apoptosis. a Representative images of TUNEL-stained sections of cardiac muscle in the Control (upper left), PG-LPS (upper right), vidarabine (lower left), and PG-LPS + vidarabine (lower right) groups. Scale bar: 25 μm. b The number of TUNEL-positive myocyte was significantly increased in the PG-LPS group (n = 4, **P < 0.01), but this increase was blocked in the PG-LPS + vidarabine group (n = 5, **P < 0.01). One-way ANOVA followed by Tukey’s post hoc test). c Expression of anti-apoptotic BCL-2 protein was significantly decreased in the cardiac muscle of PG-LPS group (n = 7, **P < 0.01), but this change was significantly blocked in the cardiac muscle of PG-LPS + vidarabine group (n = 5, *P < 0.05). One-way ANOVA followed by Tukey’s post hoc test). Full-size images of immunoblots are presented in Additional file 1: Fig. S2. Data are presented as mean ± SD and scattered dots show individual data